Baron, B.

patient response treatment study chemotherapy tumor cycle phase pcv chemotherapy glufosfamide response rate trial month toxicity grade center cancer progression temozolomide oligodendroglioma 6 months oncol od tumors second-line disease anaplastic astrocytoma criteria result eortc oncology pharmacokinetic analysis anaplastic pharmacokinetic van den tumor cells glioblastoma multiforme phase ii studies enzyme-inducing antiepileptic drugs objective response rate objective survival second-line chemotherapy oligodendroglial tumors centre cairncross jg pathology review radiation therapy infusion point success rate macdonald end point pathology glioblastoma agent success research review group 17 patients baxter oncology gmbh first-line pcv chemotherapy drug development group phase ii study netherland phase ii trials phase ii trial brain tumor group objective response eiaed anaplastic oligodendroglioma range oligodendroglial multiforme alkylating agent 12 months increase nephroprotective hydration schedule oligoastrocytoma eortc data center